Evaluation of short-term and subchronic toxicity of magnolia bark extract in rats

Liu, Zhaoping; Zhang, Xiaopeng; Cui, Wenming; Zhang, Xin; Li, Ning; Chen, Junshi; Wong, Aol; Roberts, Ashley

doi:10.1016/j.yrtph.2007.06.006

Cited by 64 publications

(45 citation statements)

References 13 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Treatment with liposomal honokiol at 25 mg·kg -1 reduced the tumour sizes by 42% compared with the untreated tumour in Lewis lung carcinoma-bearing C57BL/6 mice (Hu et al, 2008). In toxicology studies, we demonstrated that M. officinalis extract did not produce any toxic effects in the 21 and 90 day toxicity studies, and that up to 240 mg·kg -1 is a no-observedadverse-effects-level (Liu et al, 2007), which is similar to the range of doses used in the present study if it is assumed the extract has about 15% of 4-O-methyhonokiol, as described elsewhere (Oh et al, 2009). We have also evaluated the longterm toxicity including carcinogenicity of MH using a prediction program (preADME version 1.0.2, BMDRC, Seoul, Korea), and found that it was predicted not to be toxic or carcinogenic to rodents (data not shown).…”

Section: Figurementioning

confidence: 67%

4‐O‐methylhonokiol, a PPARγ agonist, inhibits prostate tumour growth: p21‐mediated suppression of NF‐κB activity

Lee

Ban

et al. 2013

British J Pharmacology

View full text Add to dashboard Cite

BACKGROUND AND PURPOSEThe effects of 4-O-methylhonokiol (MH), a constituent of Magnolia officinalis, were investigated on human prostate cancer cells and its mechanism of action elucidated. EXPERIMENTAL APPROACHThe anti-cancer effects of MH were examined in prostate cancer and normal cells. The effects were validated in vivo using a mouse xenograft model. KEY RESULTSMH increased the expression of PPARg in prostate PC-3 and LNCap cells. The pull-down assay and molecular docking study indicated that MH directly binds to PPARg. MH also increased transcriptional activity of PPARg but decreased NF-kB activity. MH inhibited the growth of human prostate cancer cells, an effect attenuated by the PPARg antagonist GW9662. MH induced apoptotic cell death and this was related to G0-G1 phase cell cycle arrest. MH increased the expression of the cell cycle regulator p21, and apoptotic proteins, whereas it decreased phosphorylation of Rb and anti-apoptotic proteins. Transfection of PC3 cells with p21 siRNA or a p21 mutant plasmid on the cyclin D1/ cycline-dependent kinase 4 binding site abolished the effects of MH on cell growth, cell viability and related protein expression. In the animal studies, MH inhibited tumour growth, NF-kB activity and expression of anti-apoptotic proteins, whereas it increased the transcriptional activity and expression of PPARg, and the expression of apoptotic proteins and p21 in tumour tissues. CONCLUSIONS AND IMPLICATIONMH inhibits growth of human prostate cancer cells through activation of PPARg, suppression of NF-kB and arrest of the cell cycle. Thus, MH might be a useful tool for treatment of prostate cancer. AbbreviationCDK, cycline-dependent kinase; CNBr, cyanogen bromide; DAPI, 4',6-diamidino-2-phenylindole; GSK-3 b, glycogen synthase kinase 3 b; IAP1, inhibitor of apoptosis 1; iNOS, inducible NOS; MH, 4-O-methylhonokiol

show abstract

Section: Figurementioning

confidence: 67%

4‐O‐methylhonokiol, a PPARγ agonist, inhibits prostate tumour growth: p21‐mediated suppression of NF‐κB activity

Lee

Ban

et al. 2013

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…or chewing gum (Porciani and Grandini, 2012). In menopausal women, the addition of a Magnolia bark extract to isoflavones, lactobacilli, calcium, and vitamin D 3 induced positive effects on insomnia, irritability, anxiety, depressed mood, asthenia, and loss of libido; adverse events were comparable in treated No mortality, ophthalmic abnormalities were found In males, significantly higher weight gains in the 120 and 240 mg/kg BW groups were observed Significant increase of blood total bilirubin and sodium values in all groups compared to the control group Slight fatty degeneration and sporadic focal necrosis in the liver of 11/40 animals (4 females and 7 males) in the 240 mg/kg BW group Lack of toxicity following dietary administration of MBE at doses up to 240 mg/kg BW per day Liu et al, 2007 (334 women) and control (300 women) groups (Agosta et al, 2011). In a similar group of women, Magnolia extract and magnesium alleviated psychoaffective and sleep disturbances (Mucci et al, 2006).…”

Section: Clinical Research On Magnoliamentioning

confidence: 92%

“…More recently, Magnolia bark has been used as a component of dietary supplements and topically applied cosmetics (Li N. et al, 2007;Liu et al, 2007).…”

Section: Biological Activitymentioning

confidence: 99%

“…The flower bud is used almost exclusively for the treatment of sinus congestion and sinus headaches, and is taken orally or applied topically. Magnolia bark, on the other hand, has a very wide range of applications as will be detailed in the present review; it has been used in Chinese and Japanese traditional medicines for the treatment of gastrointestinal (GI) disorders, anxiety, depression, nervous disorders, asthma, and allergic disease, as well for the alleviation of headaches, muscular pain, and fever (Dharmananda, 2002;Amblard et al, 2007;Li N. et al, 2007;Liu et al, 2007;Lee et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biological activity and toxicity of the Chinese herb Magnolia officinalis Rehder & E. Wilson (Houpo) and its constituents

Poivre

Duez

2017

J. Zhejiang Univ. Sci. B

106

View full text Add to dashboard Cite

Traditional Chinese herbal drugs have been used for thousands of years in Chinese pharmacopoeia. The bark of Magnolia officinalis Rehder & E. Wilson, known under the pinyin name "Houpo", has been traditionally used in Chinese and Japanese medicines for the treatment of anxiety, asthma, depression, gastrointestinal disorders, headache, and more. Moreover, Magnolia bark extract is a major constituent of currently marketed dietary supplements and cosmetic products. Much pharmacological activity has been reported for this herb and its major compounds, notably antioxidant, anti-inflammatory, antibiotic and antispasmodic effects. However, the mechanisms underlying this have not been elucidated and only a very few clinical trials have been published. In vitro and in vivo toxicity studies have also been published and indicate some intriguing features. The present review aims to summarize the literature on M. officinalis bark composition, utilisation, pharmacology, and safety.

show abstract

“…# Significantly different from Aβ 1-42 treated control (Pb.05). days or with 0-240 mg/kg for 90 days [64]. The dose (480 mg/kg for 3-week study, and 240 mg/kg for 90-day study) is similar to the dose (40 mg/kg) used 4 weeks treatment in our study.…”

Section: Discussionmentioning

confidence: 59%

4-O-methylhonokiol attenuated β-amyloid-induced memory impairment through reduction of oxidative damages via inactivation of p38 MAP kinase

Lee

Choi

Ban

et al. 2011

The Journal of Nutritional Biochemistry

View full text Add to dashboard Cite

Evaluation of short-term and subchronic toxicity of magnolia bark extract in rats

Cited by 64 publications

References 13 publications

4‐O‐methylhonokiol, a PPARγ agonist, inhibits prostate tumour growth: p21‐mediated suppression of NF‐κB activity

4‐O‐methylhonokiol, a PPARγ agonist, inhibits prostate tumour growth: p21‐mediated suppression of NF‐κB activity

Biological activity and toxicity of the Chinese herb Magnolia officinalis Rehder & E. Wilson (Houpo) and its constituents

4-O-methylhonokiol attenuated β-amyloid-induced memory impairment through reduction of oxidative damages via inactivation of p38 MAP kinase

Contact Info

Product

Resources

About